Cohance Lifesciences Ltd (COHANCE) — Board Meeting | 3 September 2026

3 September 2026 · BSE 🟡 Notable Neutral

By StockFin Research Team•AI-Assisted Analysis•Source: BSE/NSE Filings

📢 Key Event

Board approves acquisition of additional NJ Bio shares and controlling investment in Aruka Bio

🔄 What Changed

Stake in NJ Bio increased to 67.3%; control of Aruka Bio acquired; USD 18 million total investment planned

🔮 What's Next

Completion expected by end September 2026 subject to approvals

💡 Investor Takeaway

These moves deepen Cohance's ADC focus and could drive future growth through integrated services and pipeline partnerships

Cohance Lifesciences announced a strategic reorganisation involving two key transactions: acquiring an additional 244,587 shares in its subsidiary NJ Bio at USD 53 per share for approximately USD 13 million, raising its stake from 56% to 67.3% while Dr Naresh Jain retains 32.7% and remains CEO; and investing USD 5 million to gain control of Aruka Bio, acquiring 113,089 shares for about 65% non-diluted ownership, with Dr Jain also taking the CEO role there. Both deals will be funded internally and completed by end September 2026 pending regulatory approvals and definitive agreements.

📄 View Original Announcement (PDF)

📊 Stock Analysis — COHANCE ✨ Ask AI About This

About Cohance Lifesciences Ltd (COHANCE)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹17,473.75 CrP/E: 298.5ROE: 2.7%ROCE: 3.3%

View full COHANCE stock details →

📡 Get AI alerts when COHANCE files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track COHANCE — Free

💡 Ask AI about this filing

"How will the USD 18 million investment be financed?""What is the projected revenue contribution from NJ Bio integration by FY27?""How does the Aruka Bio valuation compare to peers?"

Ask AI Free →

📊 More COHANCE filings

Announcement — 28 September 2026Cohance Lifesciences Ltd announced that its trading window closes on 1 October 2026 for insiders and...
Announcement — 21 September 2026Cohance Lifesciences announced that the USFDA inspected its API facility in Andhra Pradesh from Sept...
🟡 Board Meeting — 18 September 2026Cohance Lifesciences invested USD 10 million in newly issued Compulsorily Convertible Preferred Stoc...
🟡 Voting Results — 17 September 2026Cohance Lifesciences held its 8th Annual General Meeting on 17 September 2026 via video conference, ...
🟡 Board Meeting — 17 September 2026Cohance Lifesciences held its 8th Annual General Meeting on 17 September 2026 via video conference, ...

See all COHANCE filings →

🔥 Also filed on 3 September 2026

517554NHC Foods LtdAnnual Report HINDCOMPOSHindustan Composites LtdAnnouncement 534796JUJHAR LOGISTICS LIMITEDAnnual Report 500388Shree Krishna Paper Mills & Industries LtdAnnual Report VSTLVibhor Steel Tubes LtdInsider Trading GAUDIUMIVFGaudium IVF and Women Health LtdAnnual Report

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when COHANCE files new disclosures

Track COHANCE filings, board meetings, and corporate actions. Free email alerts at 5 PM.